Ribociclib

Ribociclib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Advanced Solid Tumor、HR+/HER2- Breast Cancer、HR+, HER2-, Advanced Breast Cancer、CCNE1 Amplification。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Ribociclib 研究

• A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

  II 期招募中法国NCT04116541

• DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

  不适用招募中美国NCT06388122

• Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.

  不适用招募中英国NCT07243002

• Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

  不适用招募中美国NCT07214532

• Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  III 期招募中美国Argentina澳大利亚比利时NCT06757634

• Immunomonitoring of Breast Cancer Patients During Systemic Treatment

  不适用招募中法国NCT04925856

• Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer

  II 期招募中瑞典NCT05900206

• Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

  II 期招募中中国NCT07180160

• A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

  II 期招募中美国ArgentinaBrazil加拿大NCT07054190

• Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

  不适用招募中中国NCT07180056

• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国比利时法国德国NCT05768139

• Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

  IV 期招募中德国NCT05452213

• Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

  III 期招募中法国德国意大利荷兰NCT07237256

• Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

  II 期招募中德国西班牙NCT07195227

• Analysis of Circulating Tumor Markers in Blood

  不适用招募中法国NCT04025541

• Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

  II 期招募中奥地利比利时法国德国NCT06486883

• Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  II 期招募中美国澳大利亚加拿大德国NCT05843253

• Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

  II 期招募中美国NCT06062498

• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  III 期招募中美国Argentina澳大利亚奥地利NCT06380751

• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  III 期招募中美国Argentina澳大利亚比利时NCT07174336

• A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国澳大利亚NCT07767474

• To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer

  不适用招募中意大利NCT04660435

• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  III 期招募中美国澳大利亚奥地利比利时NCT07085767

• Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer

  不适用招募中意大利NCT07021911

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。